Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Bionomics Limited (BNOX)

2.7   -0.67 (-19.88%) 09-29 16:00
Open: 3.2 Pre. Close: 3.37
High: 3.56 Low: 2.7
Volume: 6,850,656 Market Cap: 22(M)

Technical analysis

as of: 2023-09-29 4:26:16 PM
Short-term rate:       
Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time.
Mid-term rate:       
Target: Six months: 5.03     One year: 7.47
Support: Support1: 0.93    Support2: 0.77
Resistance: Resistance1: 4.31    Resistance2: 6.4
Pivot: 1.49
Moving Average: MA(5): 1.8     MA(20): 1.58
MA(100): 2     MA(250): 3.75
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 27.2     %D(3): 16.5
RSI: RSI(14): 64.7
52-week: High: 10.89  Low: 0.93
Average Vol(K): 3-Month: 2,434 (K)  10-Days: 13,119 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BNOX ] has closed below upper band by 5.9%. Bollinger Bands are 210.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.56 - 3.58 3.58 - 3.6
Low: 2.66 - 2.68 2.68 - 2.7
Close: 2.68 - 2.7 2.7 - 2.73

Company Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Headline News

Fri, 29 Sep 2023
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% - Nasdaq

Thu, 28 Sep 2023
Sharps Technologys Acquisition and Strategic Partnership Propel ... - Best Stocks

Thu, 28 Sep 2023
Healthcare Stocks Moving Up and Down Thursday: BNOX, FEMY, AYTU, AXLA, SPRC, RNLX, SYBX, ACAD - InvestorsObserver

Thu, 28 Sep 2023
Health Care Sector Update for 09/28/2023: BNOX, BOLT, BCLI - Nasdaq

Thu, 28 Sep 2023
Significant Market Movements on September 28 2023 BNOX PTON ... - Best Stocks

Thu, 28 Sep 2023
Analyst Reiterates Positive Outlook on Gamida Cell with Strong Buy ... - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 8 (M)
% Held by Insiders 8.16e+006 (%)
% Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.15
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin (%) 0
Operating Margin (%) -346.2
Return on Assets (ttm) -21
Return on Equity (ttm) -46.2
Qtrly Rev. Growth -21.7
Gross Profit (p.s.) -5.40217e+006
Sales Per Share 3.27174e+006
EBITDA (p.s.) -1.08315e+007
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)

Stock Valuations

PE Ratio -1.27
PEG Ratio 0
Price to Book value 2.7
Price to Sales 0
Price to Cash Flow 0.09

Stock Dividends

Dividend 0
Forward Dividend 620440
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.